​

IRIDEX (IRIX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

IRIX Stock Forecast

IRIDEX (IRIX) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $3.00, with a high of $3.00 and a low of $3.00. This represents a 125.56% increase from the last price of $1.33.

High: $3 Avg: $3 Low: $3 Last Closed Price: $1.33

IRIX Stock Rating

IRIDEX stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (75.00%), 1 Hold (25.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 1 3 Strong Sell Sell Hold Buy Strong Buy

IRIX Price Target Upside V Benchmarks

TypeNameUpside
StockIRIDEX125.56%
SectorHealthcare Stocks 15.45%
IndustryMedical Device Stocks31.16%

Price Target Trends

1M3M12M
# Anlaysts-11
Avg Price Target-$3.00$3.00
Last Closing Price$1.33$1.33$1.33
Upside/Downside-125.56%125.56%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26-1---1
Feb, 26-1---1
Dec, 24--1--1
Nov, 24-11--2
Oct, 24-11--2
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 05, 2026Industrial Alliance Securities$3.00$1.47104.08%125.56%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 05, 2026Alliance Global PartnersBuyinitialise

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25
Dec 21Dec 22Dec 23Dec 24Dec 25
Reported$-0.34$-0.47$-0.59$-0.54-
Avg Forecast$-0.30$-0.52$-0.46$-0.52$-0.27
High Forecast$-0.30$-0.52$-0.46$-0.52$-0.27
Low Forecast$-0.30$-0.52$-0.46$-0.52$-0.27
Surprise %13.33%-9.62%28.26%3.85%-

Revenue Forecast

$49M $50M $52M $54M $55M $57M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25
Dec 21Dec 22Dec 23Dec 24Dec 25
Reported$53.90M$56.97M$51.87M$48.67M-
Avg Forecast$53.31M$56.95M$54.30M$49.60M$52.00M
High Forecast$53.31M$56.95M$54.30M$49.60M$52.00M
Low Forecast$53.31M$56.95M$54.30M$49.60M$52.00M
Surprise %1.11%0.03%-4.48%-1.88%-

Net Income Forecast

$-15M $-12M $-9M $-6M $-3M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25
Dec 21Dec 22Dec 23Dec 24Dec 25
Reported$-5.22M$-7.55M$-9.57M$-8.91M-
Avg Forecast$-4.07M$-4.81M$-10.86M$-8.39M$-4.35M
High Forecast$-2.54M$-3.05M$-6.90M$-8.39M$-4.35M
Low Forecast$-5.61M$-6.56M$-14.82M$-8.39M$-4.35M
Surprise %28.32%56.95%-11.85%6.24%-

IRIX Forecast FAQ

Is IRIDEX stock a buy?

IRIDEX stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that IRIDEX is a favorable investment for most analysts.

What is IRIDEX's price target?

IRIDEX's price target, set by 4 Wall Street analysts, averages $3 over the next 12 months. The price target range spans from $3 at the low end to $3 at the high end, suggesting a potential 125.56% change from the previous closing price of $1.33.

How does IRIDEX stock forecast compare to its benchmarks?

IRIDEX's stock forecast shows a 125.56% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the medical device stocks industry (31.16%).

What is the breakdown of analyst ratings for IRIDEX over the past three months?

  • March 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.

What is IRIDEX’s EPS forecast?

IRIDEX's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.27, marking a -50.00% decrease from the reported $-0.54 in 2024..

What is IRIDEX’s revenue forecast?

IRIDEX's average annual revenue forecast for its fiscal year ending in December 2025 is $52M, reflecting a 6.84% increase from the reported $48.67M in 2024.

What is IRIDEX’s net income forecast?

IRIDEX's net income forecast for the fiscal year ending in December 2025 stands at $-4.355M, representing a -51.13% decrease from the reported $-8.91M in 2024.